Evidence map›Paper›PMID 40775020›Full record

Trial reportNature communications2025

The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial.

Yeming Wang, Lianhan Shang, Lei Wu, Xia Wang, Banghan Ding, Ke Hu, Yingli He, Guangming Li, Jie Zhai, Junyan Hu and 8 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yeming Wang *National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Lianhan Shang *National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Lei Wu *Hebei Province Hospital of Traditional Chinese Medicine, Shijiazhuang, China.
Xia Wang *Youcare Pharmaceutical Co. Ltd, Beijing, China.
Banghan Ding *Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.
Ke HuRenmin Hospital of Wuhan University, Wuhan, China.ORCID http://orcid.org/0000-0001-9862-7239
Yingli HeThe First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.
Guangming LiThe Sixth People's Hospital of Zhengzhou, Zhengzhou, China.
Jie ZhaiBeijing Yolax Pharmaceutical Technology Co. Ltd, Beijing, China.
Junyan HuThe Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yingping TianThe Second Hospital of Hebei Medical University, Shijiazhuang, China.
Jun WangThe Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Li YanHebei General Hospital, Shijiazhuang, China.
Bin LiuZhujiang Hospital of Southern Medical University (The Second Clinical Medical College), Guangzhou, China.
Gengshen SongYoucare Pharmaceutical Co. Ltd, Beijing, China. songgengshen@youcareyk.com.ORCID http://orcid.org/0009-0001-3556-7459
Yuxian HeNHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. yhe@ipb.pumc.edu.cn.ORCID http://orcid.org/0000-0003-2048-6696
Chen WangNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. wangchen@pumc.edu.cn.ORCID http://orcid.org/0000-0001-7857-5435
Bin CaoNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. caobin_ben@163.com.ORCID http://orcid.org/0000-0001-6991-0350

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

YKYY017 is a SARS-CoV-2 membrane fusion inhibitor. We report efficacy and safety of inhaled YKYY017 for COVID-19 patients with mild to moderate illness from a phase 2 trial (ChiCTR2300075467). 239 patients aged 18-75 years with mostly mild COVID-19 were randomly allocated to receive aerosol inhalation of 10 or 20 mg YKYY017 or placebo once daily. The primary endpoint is the change in SARS-CoV-2 viral load from baseline to Day 4. The mean (±SE) differences in viral load change from baseline were -0.48 ± 0.27 log

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2Administration, InhalationAdolescentAdultAgedCOVID-19Double-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeViral LoadYoung AdultAntiviral Agents

Identifiers

PMID40775020
PMCPMC12332093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.